Lucy Therapeutics
Jim has over 30 years of drug discovery and research management experience. He currently serves on the board of directors, scientific advisory board and as an advisor to several biotechnology companies and venture capital firms. Previously, Jim was Vice President of Neuroscience Research at AbbVie, where he led global efforts focused on the discovery of new drugs for neurodegenerative diseases. Under his leadership more than twenty drugs entered clinical development.
This person is not in the org chart
This person is not in any offices
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.